Context-dependent adaption of EpCAM expression in early systemic esophageal cancer

The role of the epithelial cell adhesion molecule EpCAM in cancer progression remains largely unclear. High expression of EpCAM in primary tumors is often associated with more aggressive phenotypes and EpCAM is the prime epithelial antigen in use to isolate circulating tumor cells (CTCs) and characterize disseminated tumor cells (DTCs). However, reduced expression of EpCAM was associated with epithelial-to-mesenchymal transition (EMT) and reports on a lack of EpCAM on CTCs emerged. These contradictory observations might reflect a context-dependent adaption of EpCAM expression during metastatic progression. To test this, EpCAM expression was monitored in esophageal cancer at different sites of early systemic disease. Although most of the primary esophageal tumors expressed high levels of EpCAM, the majority of DTCs in bone marrow lacked EpCAM. In vitro, downregulation of EpCAM expression at the plasma membrane was observed in migrating and invading cells, and was associated with a partial loss of the epithelial phenotype and with significantly decreased proliferation. Accordingly, induction of EMT through the action of TGFβ resulted in substantial loss of EpCAM cell surface expression on esophageal cancer cells. Knock-down or natural loss of EpCAM recapitulated these effects as it reduced proliferation while enhancing migration and invasion of cancer cells. Importantly, expression of EpCAM on DTCs was significantly associated with the occurrence of lymph node metastases and with significantly decreased overall survival of esophageal cancer patients. We validated this observation by showing that high expression of EpCAM promoted tumor outgrowth after xenotransplantation of esophageal carcinoma cells. The present data disclose a dynamic expression of EpCAM throughout tumor progression, where EpCAMhigh phenotypes correlate with proliferative stages, whereas EpCAMlow/negative phenotypes associated with migration, invasion and dissemination. Thus, differing expression levels of EpCAM must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells.

[1]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[2]  Markus Munz,et al.  The emerging role of EpCAM in cancer and stem cell signaling. , 2009, Cancer research.

[3]  M. Rots,et al.  EpCAM in carcinogenesis: the good, the bad or the ugly. , 2010, Carcinogenesis.

[4]  M Vasei,et al.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.

[5]  P. Enzinger,et al.  Esophageal cancer. , 2003, The New England journal of medicine.

[6]  N. Stoecklein,et al.  Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. , 2009, Cancer research.

[7]  W. Driever,et al.  Zeb1 Regulates E-cadherin and Epcam (Epithelial Cell Adhesion Molecule) Expression to Control Cell Behavior in Early Zebrafish Development , 2013, The Journal of Biological Chemistry.

[8]  M C Miller,et al.  Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Baldus,et al.  Increased EpCAM expression in malignant insulinoma: potential clinical implications. , 2010, European journal of endocrinology.

[10]  John Yu,et al.  Epithelial Cell Adhesion Molecule Regulation Is Associated with the Maintenance of the Undifferentiated Phenotype of Human Embryonic Stem Cells* , 2010, The Journal of Biological Chemistry.

[11]  C. V. D. van de Velde,et al.  Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer , 2005, British Journal of Cancer.

[12]  I. Mackenzie,et al.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.

[13]  A. Choo,et al.  Characterization of Epithelial Cell Adhesion Molecule as a Surface Marker on Undifferentiated Human Embryonic Stem Cells , 2010, Stem cells.

[14]  J. Sleeman,et al.  Cancer metastasis as a therapeutic target. , 2010, European journal of cancer.

[15]  I. B. Briaire-de Bruijn,et al.  Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase , 2007, Molecular and Cellular Biochemistry.

[16]  A. Luebke,et al.  Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker , 2006, BMC Cancer.

[17]  N. Stoecklein,et al.  Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis , 2010, International journal of cancer.

[18]  Markus Münz,et al.  The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.

[19]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[20]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[21]  H. A. Bakker,et al.  Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins , 1997, The Journal of cell biology.

[22]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[23]  O. Gires,et al.  EpCAM and its potential role in tumor-initiating cells , 2012, Cell adhesion & migration.

[24]  Ahmad Faried,et al.  Prognostic significance of EpCAM expression in human esophageal cancer. , 2007, International journal of oncology.

[25]  B. Bao,et al.  Over‐expression of FoxM1 leads to epithelial–mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells , 2011, Journal of cellular biochemistry.

[26]  I. Tinhofer,et al.  Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition , 2012, BMC Cancer.

[27]  R. Mason,et al.  TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT) , 2005, Respiratory research.

[28]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[29]  Sabine Riethdorf,et al.  Circulating Tumor Cells and Bone Marrow Micrometastasis , 2008, Clinical Cancer Research.

[30]  Carine Maenhaut,et al.  Hallmarks of cancer: of all cancer cells, all the time? , 2012, Trends in molecular medicine.

[31]  Brigitte Mack,et al.  Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.

[32]  H. Mellstedt,et al.  Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. , 2012, Cancer treatment reviews.

[33]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[34]  B. Mack,et al.  EpCAM regulates cell cycle progression via control of cyclin D1 expression , 2013, Oncogene.

[35]  B. Mack,et al.  EpCAM Is Involved in Maintenance of the Murine Embryonic Stem Cell Phenotype , 2009, Stem cells.

[36]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.